Introduction
Chronic obstructive pulmonary disease (COPD) is a multidimensional, progressive condition characterised by persistent airflow obstruction, worsening dyspnoea and respiratory failure [
1,
2]. Exacerbations, defined as periods of acute worsening of COPD symptoms that result in additional therapy, are a hallmark of COPD [
1]. They are more prevalent in patients with more severe COPD, and are associated with an increased rate of lung function decline, worse quality of life, increased mortality, increased frequency of hospitalisations and higher healthcare costs [
3‐
6]. Even in patients with milder forms of COPD, where exacerbations are less frequent, they still impose a significant burden [
6,
7]. Therefore, effective management and prevention of exacerbations represents an important clinical challenge.
A prior history of exacerbations is the most reliable predictor of future exacerbations [
7], and, consequently, the 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report recommends that exacerbation history is used to guide treatment choice [
1]. For patients with recurrent exacerbations on long-acting bronchodilator monotherapy with long-acting muscarinic antagonists (LAMAs) or long-acting β
2-agonists (LABAs), escalation to a LAMA/LABA or LABA/inhaled corticosteroid (ICS) combination is recommended [
1].
The American Thoracic Society (ATS) strongly recommends LABA/LAMA dual therapy over LABA or LAMA monotherapy in patients who experience dyspnoea or exercise intolerance, on the basis of improved critical outcomes with dual therapy [
8]. Treatment with the LAMA/LABA fixed-dose combination tiotropium/olodaterol has demonstrated improvements in lung function, health-related quality of life and exercise capacity [
9,
10]. In addition, recent post hoc analyses showed that treatment escalation to tiotropium/olodaterol resulted in significant improvements in lung function, health status and breathlessness compared with tiotropium alone in patients who were receiving only LAMA monotherapy at study entry [
11] and in patients who were maintenance-naïve at baseline [
12]. Furthermore, there is evidence that LAMA/LABA can reduce exacerbations in patients with COPD compared with either agent alone or versus LABA/ICS [
8,
13‐
15]. In the DYNAGITO
® trial, the rate of moderate and severe exacerbations was lower with tiotropium/olodaterol compared with tiotropium (
P = 0.0498); however, the results did not meet the targeted 0.01 significance level [
13]. Expert analysis suggests that the primary statistical methodology used in the study was flawed, using a crude analysis rather than adjusting for baseline covariates [
16]. Although the reduction in exacerbation rate was smaller than anticipated in DYNAGITO, there were larger improvements in some subgroups of patients, suggesting the need for further investigation in a larger population.
In order to better understand the impact of tiotropium/olodaterol on exacerbation rates across a range of COPD disease severities, we pooled data from almost 10,000 patients with moderate-to-very severe COPD from three 1-year studies: two phase III trials in patients with and without a history of exacerbations in the previous year (TONADO
® 1 + 2) and a large phase III trial in patients with a history of exacerbations in the previous year (DYNAGITO) [
9,
13]. In both trials, patients continued with ICS if they were taking them at baseline. As severe exacerbations are less frequently reported in the clinical trial setting, large patient numbers are required to demonstrate a meaningful change in outcomes. Using this large data set, we compared the effect of dual bronchodilation with tiotropium/olodaterol 5/5 µg with tiotropium 5 µg on moderate/severe exacerbations and exacerbations leading to hospitalisation.
Additionally, the large size of this patient cohort allowed detection of effects in patient subgroups, including those with low and high exacerbation history, GOLD stage 2–4 disease (using forced expiratory volume in 1 s [FEV
1] to prognostically group patients according to the severity of their airflow limitation [
1]), and in patients with and without baseline ICS use.
Methods
Study Design
Detailed methodologies of TONADO and DYNAGITO have been published previously [
9,
13]. The TONADO trials [1237.5 (NCT01431274) and 1237.6 (NCT01431287)] included a total of 5162 patients and were two replicate, 52-week, randomised, double-blind, parallel-group, phase III trials that compared tiotropium/olodaterol (2.5/5 μg and 5/5 μg) with the monocomponents tiotropium (2.5 μg and 5 μg) and olodaterol (5 μg) in patients with moderate-to-very severe COPD, with or without previous exacerbations [
9].
The DYNAGITO trial [1237.16 (NCT02296138)] included a total of 7880 patients and was a 52-week, phase III, randomised, double-blind, active-controlled, parallel-group trial in which patients with moderate-to-very severe COPD and a history of exacerbations were assigned to receive either tiotropium/olodaterol (5/5 μg) or tiotropium (5 μg) [
13].
This post hoc analysis pooled data from the tiotropium/olodaterol 5/5 μg and tiotropium 5 μg arms of the TONADO and DYNAGITO studies. The study protocols were reviewed and approved by the independent ethics committees and/or institutional review boards of the participating centres. The studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients in these studies provided written informed consent.
Patients
Patients with COPD aged 40 years or more, a smoking history of greater than 10 pack-years and post-bronchodilator FEV
1/forced vital capacity less than 70% were recruited into the TONADO and DYNAGITO trials. In TONADO, patients were eligible for the study if they had post-bronchodilator FEV
1 < 80% predicted, whereas in DYNAGITO the eligibility criteria included post-bronchodilator FEV
1 < 60% predicted and at least one moderate/severe exacerbation in the previous year. In brief, patients were excluded from these trials if they had a recent history of myocardial infarction or a diagnosis of thyrotoxicosis or life-threatening cardiac arrhythmia (more detail on exclusion criteria has been published previously [
9,
13]). GOLD 1 patients were included in the TONADO and DYNAGITO trials. They represent a small proportion of the total number of patients recruited and may reflect enrolling errors.
Definition of Moderate and Severe COPD Exacerbations
COPD exacerbations were defined as a complex of lower respiratory events/symptoms (increase or new onset) related to underlying COPD with duration of 3 days or more and requiring a prescription of antibiotics and/or systemic steroids and/or hospitalisation (DYNAGITO trial), or a prescription of antibiotics and/or systemic steroids and/or newly prescribed maintenance respiratory medications (TONADO trials). A complex of lower respiratory events/symptoms is defined as at least two of the following: shortness of breath, sputum production (volume), change in sputum colour, cough, wheezing or chest tightness.
Moderate exacerbations were classified as those requiring an exacerbation-related prescription of oral corticosteroids and/or antibiotics, but not requiring hospitalisation. Severe exacerbations were classified as exacerbations requiring hospitalisation, including emergency room visits.
Subgroups of Interest
For this post hoc analysis, data were pooled to assess the effect of tiotropium/olodaterol versus tiotropium on moderate/severe exacerbations and exacerbations leading to hospitalisation in the following subgroups: low (0–1 moderate exacerbation in 12 months prior to trial entry) and high exacerbation history (at least two moderate or at least one severe exacerbation in 12 months prior to trial entry); exacerbation history according to 0 or 1 exacerbation in 12 months prior to trial entry; GOLD stage 2, 3 and 4; and those with and without baseline ICS use. GOLD stage 1 patients were included within the GOLD stage 2 subgroup. An exploratory analysis was also conducted on low (below the median) and high (median or higher) symptomatic patients, assessed by St. George’s Respiratory Questionnaire (SGRQ).
Statistical Analysis
To ensure comparability with data reported from other studies [
14,
15,
17], the exacerbation rates in this post hoc analysis were analysed using a negative binomial model adjusted for treatment, study, ICS use at baseline, region, GOLD stage and smoking status as fixed effects, and baseline SGRQ and number of exacerbations in previous year as covariates. All
P values are nominal. The duration of an event was not included in the calculation of a patient’s exposure. In the subgroup analysis, the corresponding subgroup was excluded from the model as a covariate.
Discussion
This post hoc analysis demonstrated that dual bronchodilation with the LAMA/LABA tiotropium/olodaterol reduces moderate-to-severe exacerbations compared with tiotropium, even in patients with infrequent exacerbation history (0–1 moderate exacerbation in previous year). Improvements were seen in GOLD stages 2–3 and in patients taking ICS at baseline. Tiotropium/olodaterol also decreased the rate of exacerbations leading to hospitalisation versus tiotropium, although the findings did not reach statistical significance in all subgroups. Exacerbations leading to hospitalisation were most evident in frequent exacerbators; however, low event rates in some of the subgroups limit interpretation in these cases.
Combining data from the TONADO and DYNAGITO trials resulted in a large pooled data set of patients with COPD treated with tiotropium/olodaterol and tiotropium, covering a broad range of phenotypes seen in clinical practice.
Subgroup analyses showed that the reduction in moderate/severe exacerbations was largely consistent across the disease spectrum (with the exception of GOLD stage 4 and non-ICS users), with a consistent magnitude of reduction across different severity grades of exacerbation history and lung function. When the data were analysed by prior history of exacerbations, a significant reduction in moderate/severe exacerbations was observed with tiotropium/olodaterol compared with tiotropium in all subgroups apart from the group of patients with no exacerbations in the previous year. As expected, the event rate was higher among patients with a high versus a low exacerbation history. This is consistent with previous studies, which indicates that the recurrence of exacerbations is linked to the history of prior exacerbations [
3].
In patients with GOLD 2 and 3 COPD, dual bronchodilation with tiotropium/olodaterol reduced the rate of moderate/severe exacerbations to a greater degree than with tiotropium. The same effect was not observed in patients with GOLD 4 COPD. This observation may reflect the nature of exacerbations in more severe disease, although an effect due to inadequate statistical power cannot be ruled out.
A significant reduction in exacerbations was observed with tiotropium/olodaterol versus tiotropium in the prior ICS use group. This could be explained by the larger size of the subgroup and the number of events reported compared with the non-ICS subgroup. It should be noted that approximately two-thirds of patients in this pooled analysis were using an ICS at baseline, which likely reflects how patients are managed in clinical practice. In addition, as is typical for clinical studies in COPD, treatment escalation and de-escalation occurred in a proportion of patients in the dual therapy and monotherapy arms, respectively. Despite this, the model applied to our analysis accounts for the treatment patients received at baseline, and therefore this is not expected to have significantly influenced these results. These results underscore the rationale for adding LABA in this setting and demonstrate its benefits beyond improvements in lung function. This adds to the body of evidence supporting the overall benefits of LAMA/LABA versus LAMA in terms of improvements in lung function, quality of life and symptom reduction [
19,
20]. Although the reduction in moderate-to-severe exacerbations was not statistically significant in this analysis in the non-ICS group, the effect size (9%) was similar to the results seen in some of the other subgroups (12% in ICS users, 10% in GOLD 3 group), even though the sample size was smaller.
In addition, in the exploratory analysis by baseline SGRQ score, patients showed a reduction in moderate/severe exacerbations with tiotropium/olodaterol in comparison with tiotropium regardless of SGRQ burden. Of note, in terms of exacerbations leading to hospitalisation, patients with low SGRQ score at baseline had a significant decrease with tiotropium/olodaterol versus tiotropium, whereas those with high SGRQ score benefitted less.
It has been suggested that a combination of LAMA/LABA can result in a significant reduction in exacerbations for patients compared with LAMA or LABA monotherapy [
8,
15]. In the ATS COPD clinical practice guidelines, a pooled analysis of 15 studies that assessed exacerbation risk revealed a reduced risk with dual LAMA/LABA therapy versus monotherapy (risk ratio 0.80; 95% CI 0.69, 0.92;
P = 0.002) [
8]. Although some of the individual studies from this meta-analysis reported significant reductions in the risk of exacerbations versus placebo [
21‐
25], when comparing LAMA/LABA with monocomponents, only numerical reductions were reported, which did not reach statistical significance [
13,
26‐
28]. However, many of these studies were not powered to detect a difference in exacerbation rates. The SPARK
® study, which was powered to evaluate exacerbation risk, examined the effect of 1-year treatment with the LAMA/LABA combination glycopyrronium/indacaterol on the rate of moderate/severe exacerbations in 2224 patients with severe-to-very severe COPD. In this study, glycopyrronium/indacaterol reduced the adjusted annual rate of exacerbations versus glycopyrronium monotherapy by 12% [
15].
Some limitations of the study are that it is a post hoc analysis and that there was no placebo group for reference. In addition, as ICS use was allowed, this makes the comparison of LAMA/LABA versus LAMA more difficult. However, its strengths include the large patient population, which is broadly representative of clinical practice and enables assessment of exacerbation rates across a range of different subgroups, thus helping to inform management strategies for different subtypes of patients with COPD.
Acknowledgements
Disclosures
Jadwiga A. Wedzicha reports grants from Johnson and Johnson, other from Novartis, Boehringer Ingelheim, AstraZeneca and GSK, and grants from GSK, AstraZeneca, Boehringer Ingelheim, Novartis, and Chiesi, outside the submitted work. Roland Buhl reports grants to Mainz University and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche, as well as personal fees from AstraZeneca, Chiesi, Cipla, Sanofi, and Teva, outside the submitted work. Dave Singh reports personal fees from Apellis, Cipla, Genentech, Peptinnovate and Skyepharma, and grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Theravance and Verona, outside the submitted work. Claus F. Vogelmeier reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols Mundipharma and Novartis, personal fees from Berlin Chemie/Menarini, CSL Behring and Teva, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), and personal fees from Nuvaira and MedUpdate, outside the submitted work. Alberto de la Hoz and Wenqiong Xue are employees of Boehringer Ingelheim. Antonio Anzueto reports personal fees from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, outside the submitted work. Peter M.A. Calverley reports grants and personal fees from GlaxoSmithKline, personal fees from AstraZeneca, Boehringer Ingelheim, Recipharm and Zambon and personal fees and other from Boehringer Ingelheim outside the submitted work.